Methods of treating hypertension
AssigneeThe Feinstein Institutes for Medical Research
InventorsWilliam Hanes, Kevin J. Tracey, Peder Olofsson
Life of this patent
Estimating the term…
Abstract
Provided are CD4+ T-cell-based compositions and methods for treating hypertension.
Claims14
A method for treating hypertension in a subject, or for reducing development of hypertension in a subject, comprising:
- administering to a subject in need thereof an amount of CD4+ T-cells, engineered to express increased levels of choline acetyltransferase relative to non-engineered CD4+ T-cells of the same type, effective to treat or reduce development of hypertension;
- wherein the CD4+ T-cells are engineered by having been transformed with a nucleic acid comprising the sequence set forth in SEQ ID NO:1 (hChAT-TAL-VP64);
- wherein the CD4+ T-cells have been modified to functionally impair, or to reduce expression of, an endogenous T-cell receptor (TCR) of the T-cell,
- wherein the CD4+ T-cells are allogenic to the subject;
- wherein the CD4+ T-cells are autologous to the subject;
- and/or wherein the CD4+ T-cells are also engineered to further comprise a suicide gene, wherein said suicide gene induces expression of the protein HSV-TK.
A method comprising administering to a subject an amount of CD4+ T-cells engineered to express increased levels of choline acetyltransferase relative to non-engineered CD4+ T-cells of the same type, wherein the CD4+ T-cells are engineered by having been transformed with a nucleic acid comprising the sequence set forth in SEQ ID NO:1 (hChAT-TAL-VP64), wherein the CD4+ T-cells have been modified to functionally impair, or to reduce expression of, an endogenous T-cell receptor (TCR) of the T-cell, wherein the CD4+ T-cells are allogenic to the subject, wherein the CD4+ T-cells are autologous to the subject, and/or wherein the CD4+ T-cells are also engineered to further comprise a suicide gene, wherein said suicide gene induces expression of the protein HSV-TK.
Dependencies are inferred from the claim text.